Study: Fosamax, Other Drugs Double Risk of Esophageal Cancer

A recent study has revealed that the use of Fosamax, along with other bone-building drugs, can double a patient’s chance of developing esophageal cancer.

Researchers from the University of Oxford in the UK examined medical records and found that the use of Fosamax and other oral bisphosphonates may increase the risk of developing esophageal cancer. The study examined data from the UK General Practice Research Database for patients who took oral bisphosphonates between January 1996 and December 2006, and followed patients for an average of seven years.

The study found that those who had filled 10 or more prescriptions for oral bisphosphonates or had used such medications for five or more years were twice as likely to develop esophageal cancer as the general population.

Additionally, the study revealed that filling just one prescription for Fosamax and other oral bisphosphonates was linked to a 30 percent increase in the likelihood of developing esophageal cancer.

Fosamax has already been linked to a rare type of thigh-bone fracture.

At Pope, McGlamry, Kilpatrick, Morrison, & Norwood, our product liability attorneys are presently investigating claims involving Fosamax. If you have experienced any serious adverse reactions, contact our Georgia DePuy Hip Replacement lawyers and discuss a potential lawsuit.

Disclaimer:  All use of the Fosamax mark is for informational and product identification purposes only. This post should not be taken as either medical or legal advice, but instead should act as a resource in providing general information that may be useful to the general public. Pope McGlamry is not affiliated with the manufacturer of Fosamax, Merck, or its distributors.